OBJECTIVE： To evaluate the effectiveness and safety of repaglinide combined with metformin versus glimepiride combined with metformin in the treatment of type 2 diabetes mellitus （T2DM）， and to provide evidence-based reference for the clinic. METHODS： Retrieved from CJFD， VIP， Wanfang database， PubMed， Embase， Medline and Cochrane Library， randomized controlled trials （RCTs） about therapeutic efficacy （HbA1c， FPG， 2 hPG） and safety （the incidence of ADR， hypoglycemia and gastrointestinal reaction） of repaglinide combined with metformin （trial group） versus glimepiride combined with metformin （control group） in the treatment of T2DM were collected. Meta-analysis was performed by using Rev Man 5.2 statistical software after data extraction and quality evaluation with Cochrane systematic evaluation manual. RESULTS： A total of 12 RCTs were included， involving 957 patients. Results of Meta-analysis showed that the decrease of 2 hPG in trial group was significantly better than control group， with statistical significance [MD＝－0.70，95％CI（－1.02，－0.38），P＜0.001]. There was no statistical significance in the decrease of HbA1c [MD＝0.00，95％CI（－0.24，0.25），P＝0.98] or FPG [MD＝0.10，95％CI（－0.17，0.36），P＝0.47]， the incidence of ADR [OR＝0.54，95％CI（0.28，1.06），P＝0.07]， hypoglycemia [OR＝0.52，95％CI（0.13，2.06），P＝0.35] or gastrointestinal reactions [OR＝0.60，95％CI（0.15，2.41），P＝0.47] between 2 groups. CONCLUSIONS： Repaglinide combined with metformin is better than glimepiride combined with metformin in reducing 2 hPG， but both of them have similar safety.